

Epidemiologic/Correlative

- UCI 14-25** Plasma Exosome Concentration in Cancer Patients Undergoing Treatment (Nelson)
- UCI 16-01** Pathway Analysis for Individualized Network Therapeutic for Cancer (PAINT) (Nelson)
- UCI 16-43** Prospective Collection of Human Colon Cancer Tissue Samples for Development of Patient Derived Xenograft Mouse Models and 3D-Vascularized Microtumor Chambers (Lyou)
- UCI 17-76**** Variations in Local Microbiome Populations in Normal Colorectal Tissue and Polyps (Whiteson)

**Therapeutic - Multi-site
(including colon)**

- UCI 15-74** Phase II Entrectinib Tx Patients with Locally Advanced / Metastatic Solid Tumors Harbor NTRK1/2/3, ROS1, ALK Gene (Ou)
- UCI 16-96** Phase I Study of the Highly-Selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors (Ou)
- UCI 17-50**** A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-399, an Antibody Drug Conjugate in Subjects with Advanced Solid Tumor (Ou)
- SWOG S1609** DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (Bota)

**COLORECTAL
CANCER**

Screening

- UCI 12-40** Atlas Colorectal Health Network (Park)
- UCI 14-30** Low Residue Diet vs. Clear Liquid Diet w/ Split dose PEG-ELS for Colon Cleansing Prior to Colonoscopy (Samarasena)

**Stage IIA/IIIA
(T2N1,T3N0,T3N1)**

Neoadjuvant

SWOG N1048 Phase II/III Trial of Neoadjuvant FOLFOX w/
Selective Use of Combined Modality Chemoradiation VS
Preoperative Combined Modality Chemoradiation for Locally
Advanced Rectal CA Pts Undergoing LAR W/Total Mesorectal
Excision (Pigazzi)

Post-Adjuvant

Stage 0-III

SWOG S0820 Phase IIA Randomized
Double Blind Placebo-Controlled Trial of
Eflornithine and Sulindac to Prevent
Recurrence of High-Risk Adenomas and
Second Primary Colorectal Cancers in
Patients with Stage 0-III Colon Cancer
(Zell)

**COLORECTAL
CANCER**

Perioperative

UCI 17-28** Immediate Adjuvant
Chemotherapy for Invasive Colonic
Adenocarcinoma (Pigazzi)

Stage IV

1st Line

UCI 15-96 A Phase III Study of
Pembrolizumab (MK-3475) vs.
Chemotherapy in Microsatellite
Instability-High (MSI-H) or Mismatch Repair Deficient
(dMMR) Stage IV Colorectal Carcinoma
(Zell)

2nd Line

ECOG-EAY131 Molecular Analysis for
Therapy Choice (MATCH) (Bota)

SWOG S1613** A Randomized Phase II
Study of Trastuzumab and Pertuzumab
(TP) Compared to Cetuximab and
Irinotecan (CETIRI) in HER2 Amplified
Irinotecan-Refractory Metastatic
Colorectal Cancer (mCRC) (Dayyani)